Breaking News

CMP Pharma, Kiel Labs In Drug Development Pact

By Kristin Brooks | March 3, 2014

To develop two NDA products in liquid dosage form

CMP Pharma and Kiel Laboratories have signed an agreement to develop and commercialize two new drug products. Both drugs are approved by the FDA in solid dosage forms and CMP will file NDAs to gain approval for an alternate liquid dosage form.
 
CMP Pharma is a specialty pharmaceutical company located in Farmville, NC that develops and manufactures a portfolio of high-value topical and liquid pharmaceutical products. Kiel Laboratories, Inc., located in Flowery Branch, GA, provides drug development, regulatory and intellectual property services, and specializes in identification of and regulatory strategies around 505(b)(2) NDA submissions.     
 
Gerald Sakowski, chief executive officer of CMP Pharma, said, “These two products are excellent complements to our line of niche specialty pharmaceutical products. This is another chapter in our long history of developing stable, ready-to-use liquid dosage forms that make life easier on the consumer, the physician and the pharmacist.”

Related Contract Manufacturing:

Related Packaging:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent